

Ref: FOI/GS/ID 6377

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

09 December 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to colorectal cancer [CRC].

You asked:

- 1. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?*
- 2. Of these patients how many are locally advanced, recurrent, metastatic and unresectable head and neck cancer patients?*

Locally advanced

Recurrent

Metastatic

Unresectable

Unknown

- 3. Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?*

Carboplatin (only or in combination with 5-FU)

Cisplatin (only or in combination with 5-FU)

Cetuximab with/without chemotherapy

Cetuximab with radiotherapy

Pembrolizumab monotherapy

Pembrolizumab with chemotherapy

Nivolumab

Docetaxel (only or in combination with 5-FU)

Fluorouracil (5FU)

Radiotherapy only

Other

- 4. Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?*

5. Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];

Aflibercept

Bevacizumab

Capecitabine

CAPIRI

CAPOX

Cetuximab not in combination with FOLFIRI or FOLFOX

Cetuximab in combination with FOLFIRI

Cetuximab in combination with FOLFOX

Irinotecan

FOLFIRI

FOLFOX

Oxaliplatin

Panitumumab not in combination with FOLFIRI or FOLFOX

Panitumumab in combination with FOLFIRI

Panitumumab in combination with FOLFOX

Nivolumab

Raltitrexed

Ramucirumab

Regorafenib

Sorafenib

5FU only

Tegafur Uracil + 5FU

Trifluridine–tipiracil

XELOX

Other

6. Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma :

Sunitinib

Avelumab + Axitinib

Axinitib

Cabozantinib

Everolimus

Lenvantinib + Everolimus

Nivolumab

Nivolumab + Ipilimumab

Pazopanib

Pembrolizumab + Axitinib

Sunitinib

Temsirolimus

Tivozanib

7. Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?

Trust response:

1. 95

2.

Locally advanced 1

Recurrent 1
Metastatic 1
Unresectable
Unknown 92

3.

Carboplatin (only or in combination with 5-FU) 8
Cisplatin (only or in combination with 5-FU) 4
Cetuximab with/without chemotherapy 0
Cetuximab with radiotherapy 0
Pembrolizumab monotherapy 0
Pembrolizumab with chemotherapy 0
Nivolumab 2
Docetaxel (only or in combination with 5-FU) 2
Fluorouracil (5FU) 4
Radiotherapy only 64
Other 4

4. The only head and neck cancer trial we are currently recruiting to is:
BRITER Study (Brain Imaging to predict Toxicity in Elderly patients after
Radiotherapy)

IRAS no: 216343

IRAS category: Study administering questionnaires/interviews for quantitative
analysis, or using mixed quantitative/qualitative methodology

There are 7 patients recruited to it

5. 93

Aflibercept 0
Bevacizumab 0
Capecitabine 21
CAPIRI 6
CAPOX 0
Cetuximab not in combination with FOLFIRI or FOLFOX 0
Cetuximab in combination with FOLFIRI 5
Cetuximab in combination with FOLFOX 1
Irinotecan 0
FOLFIRI 14
FOLFOX 8
Oxaliplatin 0
Panitumumab not in combination with FOLFIRI or FOLFOX 0
Panitumumab in combination with FOLFIRI 0
Panitumumab in combination with FOLFOX 0
Nivolumab 3
Raltitrexed 1
Ramucirumab 0
Regorafenib 0
Sorafenib 0
5FU only 1
Tegafur Uracil + 5FU 0
Trifluridine–tipiracil 6
XELOX Not recognised
Other 5
6. 110

Sunitinib see below

Avelumab + Axitinib 0

Axinitib 1

Cabozantinib 1

Everolimus 0

Lenvantinib + Everolimus 0

Nivolumab 0

Nivolumab + Ipilimumab 1

Pazopanib 1

Pembrolizumab + Axitinib 0

Sunitinib 1

Temsirolimus 0

Tivozanib 0

7. There are currently no renal cell cancer trials running.